8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 28, 2026·SEC
Pacira BioSciences, Inc.(PCRX)Earnings, Financials & Key Ratios
PCRX•NASDAQ
$25.82
161.4× P/E·Price updated Jul 7, 2026
AboutPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Show more
- Revenue$726M+3.6%
- EBITDA$124M+2196.4%
- Net Income$7M+107.1%
- EPS (Diluted)0.16+107.4%
- Gross Margin79.39%+4.9%
- EBITDA Margin17.12%+2115.8%
- Operating Margin4.58%+143.8%
- Net Margin0.97%+106.8%
- ROE0.96%+107.9%
PCRX Price & Volume
Pacira BioSciences, Inc. (PCRX) stock price & volume — 10-year historical chart
Loading chart...
EXPAREL Reliance Masks Structural Operating Margin Compression
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Generic competition and reimbursement
Key Thesis Takeaways
- Pacira BioSciences faces a challenging outlook as its core EXPAREL franchise struggles with market saturation, evidenced by revenue growth fluctuating between 1.1% and 6.5% over the last ten quarters.
- While the company has successfully deleveraged its balance sheet to a debt-to-equity ratio of 0.02, persistent operating inefficiencies and high stock-based compensation averaging over $13M per quarter continue to weigh on bottom-line profitability.
- Investors should monitor whether the company can pivot toward sustainable earnings growth or if competitive pressures will further erode its current 3.9% operating margin.
Verdict Logic
while the company has successfully reduced its debt-to-equity ratio to 0.02, the forward P/E of 8.77 reflects significant market skepticism regarding the sustainability of its core product revenue and long-term profitability.
PCRX Growth Metrics
Pacira BioSciences, Inc. (PCRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.3%
5 Years11.07%
3 Years2.89%
TTM4.57%
Profit CAGR
10 Years14.25%
5 Years-45.44%
3 Years-23.82%
TTM108.97%
EPS CAGR
10 Years14.87%
5 Years-45.51%
3 Years-22.22%
TTM105.26%
Return on Capital
10 Years0.72%
5 Years2.82%
3 Years1.07%
Last Year2.79%
PCRX Recent Earnings
Pacira BioSciences, Inc. (PCRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.60-1.6%
$0.61
Rev
$177M+3.2%
$172M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.57-32.9%
$0.85
Rev
$197M-1.7%
$200M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.70+7.7%
$0.65
Rev
$180M-11.1%
$202M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.74+2.8%
$0.72
Rev
$181M-0.7%
$182M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.60vs $0.61-1.6% | $177Mvs $172M+3.2% |
| Q1 2026 | Feb 26, 2026 | $0.57vs $0.85-32.9% | $197Mvs $200M-1.7% |
| Q4 2025 | Nov 6, 2025 | $0.70vs $0.65+7.7% | $180Mvs $202M-11.1% |
| Q3 2025 | Aug 5, 2025 | $0.74vs $0.72+2.8% | $181Mvs $182M-0.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pacira BioSciences, Inc. (PCRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.82 | $1.02B | 161.38 | 3.63% | 0.97% | 0.96% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $4.91 | $1.83B | 11.42 | 8.53% | -11.27% | — | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $33.12 | $1.34B | 27.83 | 27.37% | 6.35% | 29.49% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — |
Compare PCRX vs Peers
Pacira BioSciences, Inc. (PCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PCRX SEC Filings & Documents
Pacira BioSciences, Inc. (PCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PCRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PCRX Frequently Asked Questions
Pacira BioSciences, Inc. (PCRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Pacira BioSciences, Inc.'s revenue?
Pacira BioSciences, Inc. (PCRX) reported $734.9M in revenue for fiscal year 2025. This represents a 5177% increase from $13.9M in 2008.
How fast is Pacira BioSciences, Inc. growing?
Pacira BioSciences, Inc. (PCRX) grew revenue by 3.6% over the past year. Growth has been modest.
Is PCRX profitable?
Yes, Pacira BioSciences, Inc. (PCRX) is profitable, generating $9.3M in net income for fiscal year 2025 (1.0% net margin).
Dividend & Returns
What is PCRX's return on equity?
Pacira BioSciences, Inc. (PCRX) has a return on equity (ROE) of 1.0%. This is below average, suggesting room for improvement.
What is Pacira BioSciences, Inc.'s free cash flow?
Pacira BioSciences, Inc. (PCRX) generated $132.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.